Clinical trial NCT02111499: Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test
Official title: A Randomized, Controlled, Observer-blind Psoriasis Plaque Test to Investigate the Anti-psoriatic Efficacy, Tolerability and Safety (Skin Atrophy) of LAS41004 Formulations in Patients With Mild to Moderate Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Psoriasis
Keywords: psoriasis plaque test
topical application
atrophy measure
Lead sponsor: Almirall, S.A.
Sponsor class: INDUSTRY
Collaborators: name: proDERM GmbH
First posted: 2014-04-11
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clinical investigation of anti-psoriatic efficacy and atrophy

Detailed description: In this trial three concentrations of bexarotene in combination with a fixed concentration of betamethasone dipropionate, as well as monotherapy with bexarotene, will be investigated regarding their efficacy, tolerability and safety in patients with mild to moderate plaque psoriasis and will be compared with the vehicle and an active comparator.

Since a side effect of the application of corticosteroids is skin atrophy, additionally three non-lesional test areas (not affected by psoriasis) on the volar forearm will be treated with the active reference product, one of the fixed combinations and the vehicle. Skin atrophy will be investigated by visual assessment and ultrasound at these test areas

Eligibility criteria: Main Inclusion Criteria:

* 18 to 75 years of age
* Men and women with skin type I to IV (Fitzpatrick 1974).
* Suffering from mild to moderate plaque psoriasis of at least 6 months duration that is amenable to local therapy.
* With at least one stable psoriatic plaque in an area sufficient for product application meeting the following criteria:

  * Located at the trunk and/or the extremities (plaques located on the head, palms, or soles of the feet, intertriginous or genitoanal areas are not suitable).
  * Plaques with a clinical score of the parameter erythema and or induration of ≥ 2 for each sign at the screening visit. At Day 1 each parameter has to be scored ≥ 2.
  * Where more than one plaque is to be used, plaques should be comparable, with at least "2" in each score for erythema and induration.
  * • Body surface area (BSA) involvement \< 10 %.
* Prepared to give written informed consent specific to the trial, before any assessment is performed.
* • In the case of women of childbearing potential using reliable methods of contraception which result in a low failure rate i.e. less than 1% per year (e.g. contraceptive implants or injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomized partner). During the study an additional barrier method (e.g. condoms) should be used. Non-childbearing potential is defined as surgical sterilization (hysterectomy, ovariectomy or tubal ligation), postmenopausal status (continuous amenorrhea of at least 2 years).
* In the case of men with partners of childbearing potential willingness of using condoms during the study conduct and 1 month after end of treatment.

Main Exclusion Criteria:

* • Patients who need systemic treatment for their psoriasis.

  * Severe forms of psoriasis or forms of psoriasis other than chronic plaque psoriasis,
  * Systemic treatment (see table below):

Corticosteroids, antibiotics 4 weeks prior to trial Day 1 and during conduct of trial Retinoids Ciclosporin Methotrexate Fumaric acid esters 3 months prior to trial Day 1 and during conduct of trial Anti-inflammatory substances, NSAIDs 2 weeks prior to trial Day 1 and during conduct of trial Biologics 6 months prior to trial Day 1 and during conduct of trial

* Topical treatment of all other body regions with corticosteroids or immunosuppressants where more than 20 % of the body surface area is treated.
* Diseases:

Significant skin infections caused by bacteria, viruses or fungi, including but not limited to tuberculosis, syphilis or varicella zoster infection Parasitic infections

Primary outcomes:
measure: Area under the curve, AUC, of the width of the echo-lucent band based on sonography measurements
timeFrame: day 1 vs day 29
Secondary outcomes:
measure: erythema and induration
timeFrame: day 1 vs day 29
measure: local skin tolerability
timeFrame: every day for 28 days
measure: atrophy
timeFrame: day1 vs day 29
measure: assessment of (serious) Adverse Events
timeFrame: from baseline to day 29
Other outcomes:
Locations:
city: Schenefeld
country: Germany
facility: proDERM GmbH
state: Schleswig-Holstein
Study officials:
affiliation: proDERM GmbH
name: Kirstin Deuble-Bente, Dr med
role: PRINCIPAL_INVESTIGATOR
References: